Comparative chemical characterisation of chitosans and their impact on growth, faecal consistency and microbiota composition in weaned piglets

This study characterizes three distinct chitosan formulations and evaluates their effects on weaned piglets, finding that while advanced chemical analysis is crucial for precision nutrition, the tested dosages did not significantly improve growth, faecal consistency, or microbiota composition, suggesting that a higher threshold dose may be required to effectively manage post-weaning diarrhoea.

The Gist

The Big Picture: A Piglet's Tough Transition

Imagine a piglet's life like a human child starting school. The first few weeks are chaotic. They are separated from their mom (the "nursery"), their diet changes abruptly from milk to solid food, and they are stressed. This is the perfect storm for a tummy ache called Post-Weaning Diarrhoea (PWD).

In the past, farmers used "magic bullets" like strong antibiotics or high doses of zinc to fix this. But because we don't want to create "superbugs" (bacteria that antibiotics can't kill) or leave metal in our food, those options are being banned. Farmers are desperate for a new, natural solution.

Enter Chitosan. Think of chitosan as a "gut guardian" made from the shells of crabs and shrimp. Scientists hoped it could act like a shield, calming the piglet's stomach and fighting bad bacteria without the side effects of drugs.

The Problem: "Chitosan" is a Confusing Name

Here is the catch: "Chitosan" isn't just one thing. It's like saying "fruit." An apple is a fruit, but so is a durian. They are both fruit, but they act very differently.

Chitosan comes in different sizes and shapes:

• COS (The Tiny Ones): Tiny fragments, like crumbs.
• LMW (The Small Ones): Small chunks.
• MMW (The Medium Ones): Medium-sized chunks.

The researchers realized that previous studies were confusing because they were testing different "fruits" but calling them all "fruit." Some studies said chitosan worked; others said it did nothing. To solve this, the team decided to be very precise. They picked three specific types of chitosan, measured them down to the atomic level (like weighing every single grain of sand in a bucket), and then tested them on pigs.

The Experiment: Two Big Trials

The team ran two massive field tests with hundreds of piglets at a research farm in the Netherlands.

Trial 1: The "Tiny Crumbs" (COS)
They tested a very small, water-soluble type of chitosan at three different doses (low, medium, high).

• The Result: It was a bust. The piglets didn't grow faster, they didn't poop better, and they didn't get sick less often. In fact, the highest dose actually made the feed slightly less efficient (the pigs ate the same amount but gained less weight).
• The Lesson: Maybe the dose was too low, or maybe these tiny crumbs just weren't the right tool for the job.

Trial 2: The "Chunks" (LMW and MMW)
Next, they tried a small chunk (LMW) and a medium chunk (MMW) at a very low dose (0.01%).

• The Result: Again, no magic. The piglets on chitosan performed exactly the same as the piglets on the regular diet. Their poop was the same, their gut bacteria were the same, and they didn't shed fewer disease-causing bacteria.

The Detective Work: Why Did It Fail?

If chitosan is supposed to be a "gut guardian," why didn't it work? The researchers played detective and found a few clues:

1. The "Sticky" Trap: When they tried to measure the chitosan in the pig feed, they found a problem. The feed was mostly made of corn (maize). It turns out that chitosan is like a magnet, and the corn is like a sticky surface. When the chitosan hit the corn, it stuck to it and became invisible to their testing equipment. It's like trying to find a specific red Lego brick in a pile of red sand; the sand hides the brick.
2. The "Wrong Size" Theory: The doses used were very low. The researchers suspect that maybe they needed a much higher dose to see a benefit, but they were afraid to go higher because they didn't know if it would be safe.
3. The "Healthy Pig" Factor: The piglets in the study were actually quite healthy to begin with. It's hard to see if a medicine works if the patient isn't very sick. The piglets didn't have a massive outbreak of diarrhea, so the chitosan didn't have a big problem to solve.

The Takeaway: It's Not a "No," It's a "Not Yet"

The study didn't prove that chitosan is useless. Instead, it proved that we don't know enough about it yet.

• Analogy: Imagine trying to fix a car engine with a wrench. If you use the wrong size wrench, the bolt won't turn. You might say, "Wrenches don't work on cars!" But the real issue is that you need the right size wrench.
• The Conclusion: Chitosan is a promising tool, but we need to figure out the exact size (molecular weight) and the exact amount (dose) needed to work. We also need better ways to measure it so we know exactly how much is actually in the feed and how much is stuck to the corn.

In short: The researchers tried to find a natural "superhero" for piglets' tummies. They found that the current versions of the superhero weren't quite strong enough or the right size to make a difference in a healthy herd. But the research has given them a better map for finding the real superhero in the future.

Technical Summary

1. Problem Statement

The management of Post-Weaning Diarrhoea (PWD) in piglets is a critical challenge in the livestock industry, particularly following the European Union's ban on high-dose zinc oxide (2022) and the restriction of critically important antibiotics like colistin. PWD is primarily caused by Enterotoxigenic Escherichia coli (ETEC) and is exacerbated by weaning stress and dietary changes.
While chitosan and chito-oligosaccharides (COS) are proposed as alternatives, their efficacy is inconsistent in the literature. A major barrier to understanding this inconsistency is the lack of standardized chemical characterization of the products used. Chitosan is a heterogeneous biopolymer with variable molecular weights (MW), degrees of acetylation (DA), and polymer distributions, yet many studies rely on a single CAS number (9012-76-4) without defining specific physicochemical properties. This study aims to bridge the gap between precise chemical characterization and zootechnical performance to determine if specific chitosan profiles can effectively replace antibiotics/zinc.

2. Methodology

A. Scoping Review and Product Selection

• Review: A semi-systematic review of 21 peer-reviewed studies (2007–2020) analyzed the relationship between chitosan characteristics (MW, DA, inclusion levels) and Average Daily Gain (ADG).
• Selection: Based on the review, three distinct GMP-grade products were selected for comparative testing:
  1. COS-HCl: Chito-oligosaccharide hydrochloride (low MW, water-soluble).
  2. LMW Chitosan: Low Molecular Weight chitosan (micropowder).
  3. MMW Chitosan: Medium Molecular Weight chitosan.

B. Advanced Chemical Characterization

The study employed sophisticated analytical techniques to define the products beyond manufacturer Certificates of Analysis (CoA):

• ¹H-NMR: To determine the Degree of Acetylation (DA).
• SEC-RI-MS (Size Exclusion Chromatography with Refractive Index and Mass Spectrometry): To determine Molecular Weight (Mw), Number Average Molecular Weight (Mn), Degree of Polymerization (DP), and oligomeric distribution.
• SEC-RI-MALLS: Used for LMW and MMW chitosans to measure dispersity and molar mass distribution.
• Enzymatic UHPLC-MS: Developed to quantify chitosan content in complex feed matrices (premix and feed) by enzymatic depolymerization followed by mass spectrometry.

C. In Vivo Zootechnical Trials

Two 42-day field trials were conducted at Schothorst Feed Research (The Netherlands) using clinically healthy weaned piglets (Tempo x TN70).

• Trial 1 (Dose Response): Tested COS-HCl at three inclusion levels (0.025%, 0.05%, 0.10%) vs. Negative Control (NC).
  • N: 192 piglets; 48 per treatment.
• Trial 2 (Type Comparison): Tested LMW and MMW chitosans at 0.01% inclusion vs. NC.
  • N: 288 piglets; 96 per treatment.
• Measurements:
  • Zootechnical: Body Weight (BW), Average Daily Gain (ADG), Feed Conversion Ratio (FCR), Average Daily Feed Intake (ADFI).
  • Health: Faecal consistency scores (FS), veterinary interventions, mortality.
  • Microbiology: Quantitative PCR for F4-ETEC shedding; 16S rRNA metataxonomic sequencing for gut microbiota composition (alpha and beta diversity).

3. Key Contributions

1. High-Resolution Characterization: The study provided the first detailed oligomeric and polymeric profiles of the selected chitosans, revealing significant heterogeneity not captured by standard CoAs.
   • COS-HCl: Mw 0.824 kDa, DA 9.5%, composed mainly of short oligomers (DP 3–5).
   • LMW Chitosan: Mw 14.4 kDa, DA 6.5%, a mixture of polymers and oligomers (down to dimers).
   • MMW Chitosan: Mw 116 kDa, DA 15%, exclusively polymeric (15–600 kDa range).
2. Analytical Method Development: The authors developed and tested methods to quantify chitosan in feed. They successfully quantified MMW chitosan in premix using an enzymatic UHPLC-MS method but highlighted significant challenges in detecting COS and LMW chitosan in complex feed matrices due to signal suppression and matrix interference (e.g., maize binding).
3. Evidence-Based Dose Selection: The trials utilized doses informed by the scoping review and previous literature, specifically testing low inclusion levels (0.01%–0.1%) relevant to current regulatory limits.

4. Results

Chemical Characterization

• The three products were chemically distinct. COS-HCl was a defined mixture of short oligomers, while LMW and MMW were polymeric with different dispersity and size ranges.
• Quantification Challenges: In Trial 1, SEC-RI-MS showed that while COS-HCl could be detected in premix, its signal was almost completely suppressed in the final feed matrix (likely due to binding with maize components). The enzymatic method successfully quantified MMW chitosan in premix (recovery consistent with inclusion) but failed to provide reliable quantification for LMW and COS due to solubility issues during washing steps and salt interference.

Zootechnical Performance (Trials 1 & 2)

• Growth Performance: Neither trial showed statistically significant improvements in ADG, ADFI, or FCR for any chitosan treatment compared to the negative control.
  • Trial 1: COS-HCl at 0.025–0.1% resulted in ADG changes ranging from -33 to -12 g/d (non-significant).
  • Trial 2: LMW and MMW at 0.01% resulted in ADG changes of -7 and +3 g/d respectively (non-significant).
• Faecal Consistency: No significant differences were observed in faecal scores between treatments and controls. Faecal scores remained generally high (optimal) throughout the trials, indicating a low disease pressure environment.
• ETEC Shedding: F4-ETEC shedding levels at days 7 and 14 were not significantly different between treated and control groups.
• Microbiota: 16S rRNA sequencing revealed no significant differences in bacterial composition (family/genus level), alpha-diversity (Chao1, Shannon, Simpson), or beta-diversity (Bray-Curtis) between treatments.

Statistical Observations

• In Trial 1, a polynomial regression suggested a linear dose-response relationship where increasing COS-HCl doses slightly worsened Feed Conversion Ratio (FCR) in the first 14 days, though this was not statistically significant in pairwise comparisons.
• Mortality and veterinary intervention rates were low and did not differ significantly between groups.

5. Significance and Conclusion

• Negative but Informative Outcome: The study concludes that under the specific conditions of these trials (low disease pressure, specific inclusion levels, and maize-based diets), the tested chitosans did not improve growth or gut health.
• The "Threshold" Hypothesis: The authors suggest that the lack of efficacy may be due to sub-therapeutic dosing. The doses used (0.01%–0.1%) may have been too low to elicit a biological effect or may have disrupted microbial equilibrium without providing a compensatory benefit. A higher "threshold dose" might be required for efficacy.
• Matrix Interference: The study highlights that maize-based diets may bind chitosan, reducing bioavailability and complicating detection. This suggests that efficacy might be diet-dependent.
• Regulatory Implications: The successful development of an enzymatic method to quantify MMW chitosan in premix is a crucial step toward meeting EU regulatory requirements for feed additive characterization and homogeneity.
• Future Directions: The authors recommend further research into:
  1. Higher inclusion doses to establish a dose-response curve.
  2. Challenge studies (specifically inducing PWD) to test efficacy under disease pressure.
  3. Continued refinement of analytical methods to overcome matrix interference in feed.

In summary, while chitosan remains a promising candidate for antibiotic alternatives, this study underscores that chemical heterogeneity and dosage are critical variables. Without precise characterization and potentially higher doses, chitosan may not deliver the expected zootechnical benefits in low-stress environments.